1. Home
  2. CELC vs WOW Comparison

CELC vs WOW Comparison

Compare CELC & WOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CELC
  • WOW
  • Stock Information
  • Founded
  • CELC 2011
  • WOW 2001
  • Country
  • CELC United States
  • WOW United States
  • Employees
  • CELC N/A
  • WOW N/A
  • Industry
  • CELC Medical Specialities
  • WOW Cable & Other Pay Television Services
  • Sector
  • CELC Health Care
  • WOW Telecommunications
  • Exchange
  • CELC Nasdaq
  • WOW Nasdaq
  • Market Cap
  • CELC 440.0M
  • WOW 358.1M
  • IPO Year
  • CELC 2017
  • WOW 2017
  • Fundamental
  • Price
  • CELC $13.04
  • WOW $4.10
  • Analyst Decision
  • CELC Strong Buy
  • WOW Buy
  • Analyst Count
  • CELC 6
  • WOW 2
  • Target Price
  • CELC $30.67
  • WOW $6.50
  • AVG Volume (30 Days)
  • CELC 196.9K
  • WOW 286.9K
  • Earning Date
  • CELC 08-13-2025
  • WOW 08-07-2025
  • Dividend Yield
  • CELC N/A
  • WOW N/A
  • EPS Growth
  • CELC N/A
  • WOW N/A
  • EPS
  • CELC N/A
  • WOW N/A
  • Revenue
  • CELC N/A
  • WOW $619,400,000.00
  • Revenue This Year
  • CELC N/A
  • WOW N/A
  • Revenue Next Year
  • CELC N/A
  • WOW N/A
  • P/E Ratio
  • CELC N/A
  • WOW N/A
  • Revenue Growth
  • CELC N/A
  • WOW N/A
  • 52 Week Low
  • CELC $7.58
  • WOW $3.87
  • 52 Week High
  • CELC $19.77
  • WOW $5.80
  • Technical
  • Relative Strength Index (RSI)
  • CELC 60.10
  • WOW 47.94
  • Support Level
  • CELC $12.48
  • WOW $3.96
  • Resistance Level
  • CELC $13.60
  • WOW $4.19
  • Average True Range (ATR)
  • CELC 0.74
  • WOW 0.13
  • MACD
  • CELC 0.04
  • WOW 0.02
  • Stochastic Oscillator
  • CELC 75.91
  • WOW 70.61

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

About WOW WideOpenWest Inc.

WideOpenWest Inc is a cable operator and broadband service, provider. The company serves residential, business and wholesale customers in Illinois, Michigan, Indiana, Ohio, Kansas, Tennessee, Maryland, and South Carolina. Its service portfolio consists of high-speed internet, data, voice, cloud, and cable television services. The company operates in one business segment that is Broadband Services. The majority of the revenue is generated from the subscription service revenue received.

Share on Social Networks: